[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

Recruiting now · Phase 2

Conditions studied: Acute Cellular Graft Rejection, Cardiac Sarcoidosis, Myocarditis Due to Drug

In brief

Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging. Since accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of \[68Ga\]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients. The identification of a correlation between \[68Ga\]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.

Key facts

Study ID

NCT05499637

Run by

John O. Prior

People needed

69

Starts

2023-01-17

Expected to finish

2027-01-01

Last updated by the study team

2026-05-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• signed written informed consent
• male or female
• age ≥ 18 years
• patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I)
• SOC clinical follow-up at the cardiology department in CHUV.

You may not qualify if…

• The presence of any one of the following exclusion criteria will lead to exclusion of the participant:
• absence of a signed written informed consent
• patients aged < 18 years
• claustrophobia
• myocardial ischemia in non-invasive perfusion test or coronarography in group II and III
• clinically unstable cardiovascular conditions, including:
• clinically unstable brady-tachyarrhythmia
• severe and symptomatic hypo- or hypertension with documented systolic blood pressure < 90 mmHg or ≥220 mmHg respectively
• cardiogenic shock.
• women who are pregnant or breast feeding
• intention to become pregnant during the course of the study in group II
• previous enrolment into the current study
• moderate to severe renal insufficiency (GFR < 45 mL/min/1,73 m2), with contra-indication to the administration of Gadolinium in group II and III
• enrollment of the investigator, his/her family members, employees and other dependent persons
• history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment
• insufficient knowledge of project language, inability to give consent or to follow procedures
• the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings

Where it is running

• Centre Hospitalier Universitaire Vaudois — Lausanne, Canton of Vaud, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.